Market Access Views & Analysis

Views & Analysis

Market access roundup: Government grillings for Vertex and U...

It was a month characterised by governments butting heads with pharma over pricing both in the UK and across the pond.

Views & Analysis

The great regulatory catch-up

Medical device manufacturers have a lot to learn from the pharmaceutical sector which, for well over a decade, has been subject to the sorts of rigorous electronic reporting standards soon

Views & Analysis

The shadow of Brexit on speed of access

No-one can miss the ongoing saga that is the UK’s exit from the European Union (EU).

Market Access

eyeforpharma Barcelona 2019

Views & Analysis

Science Molecule, Molecular DNA Model Structure, business teamwork conceptMolecular, DNA and atom model in science research labMolecular, DNA and atom model in science research lab setting in studio.

Rare Disease Day: How the patient voice can tear down barrie...

To have any impact, patient engagement needs to start with the drug development pathway, not at the point of licensing. That’s especially true in the rare disease space, where the unme

Views & Analysis

Market access roundup: UK HTA shakeups as Brexit fears deepe...

With a Brexit deal still out of sight, there have been intensified warnings in the UK about potential disruptions to medicine supplies that could follow a no-deal scenario.

Market access roundup: Government grillings for Vertex and U...

The great regulatory catch-up

The shadow of Brexit on speed of access

eyeforpharma Barcelona 2019

Rare Disease Day: How the patient voice can tear down barrie...

Market access roundup: UK HTA shakeups as Brexit fears deepe...

Delivering the right behavioural ingredients for the moment,...

How to meet your physicians where they are online

Views & Analysis

Editor's Picks